Is There a Place for Thoracoscopic Enucleation of Esophageal Gastrointestinal Stromal Tumors?


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 30 9 2018
medline: 4 12 2019
entrez: 30 9 2018
Statut: ppublish

Résumé

 Esophageal gastrointestinal stromal tumors (E-GISTs) represent less than 1% of all GISTs. The rarity of this lesion precludes the realization of randomized studies, and its treatment remains a matter of debate. We aimed to evaluate the feasibility of enucleation by video-assisted thoracic surgery (VATS) for low- to intermediate-risk E-GIST.  We performed a retrospective review of patients treated by enucleation through VATS between January 2004 and January 2014 and reviewed the literature.  We included five patients (four men and one woman). Mean age was 53 years (range: 49-79). Three patients were diagnosed because of dysphagia and two others incidentally. The diagnosis was made by immunostaining demonstrating CD117 expression on tumor cells. The mitotic index of all E-GISTs was low (≤ 5 per 50 high-power field). Median postoperative follow-up was 5.5 years, and there was no recurrence.  Thoracoscopic enucleation of E-GIST seems to represent a valuable option as the postoperative morbidity/mortality is low and the oncological outcome is good for low-to-intermediate grade of malignity tumors.This is a retrospective study focused on minimally invasive treatment of E-GIST. We evaluated the feasibility of VATS enucleation of low-to-medium grade of malignity E-GIST.

Sections du résumé

BACKGROUND BACKGROUND
 Esophageal gastrointestinal stromal tumors (E-GISTs) represent less than 1% of all GISTs. The rarity of this lesion precludes the realization of randomized studies, and its treatment remains a matter of debate. We aimed to evaluate the feasibility of enucleation by video-assisted thoracic surgery (VATS) for low- to intermediate-risk E-GIST.
METHODS METHODS
 We performed a retrospective review of patients treated by enucleation through VATS between January 2004 and January 2014 and reviewed the literature.
RESULTS RESULTS
 We included five patients (four men and one woman). Mean age was 53 years (range: 49-79). Three patients were diagnosed because of dysphagia and two others incidentally. The diagnosis was made by immunostaining demonstrating CD117 expression on tumor cells. The mitotic index of all E-GISTs was low (≤ 5 per 50 high-power field). Median postoperative follow-up was 5.5 years, and there was no recurrence.
CONCLUSION CONCLUSIONS
 Thoracoscopic enucleation of E-GIST seems to represent a valuable option as the postoperative morbidity/mortality is low and the oncological outcome is good for low-to-intermediate grade of malignity tumors.This is a retrospective study focused on minimally invasive treatment of E-GIST. We evaluated the feasibility of VATS enucleation of low-to-medium grade of malignity E-GIST.

Identifiants

pubmed: 30267389
doi: 10.1055/s-0038-1670662
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-588

Informations de copyright

Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

None.

Auteurs

Charlotte Cohen (C)

Department of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, Nice Cedex, France.

Daniel Pop (D)

Department of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, Nice Cedex, France.

Philippe Icard (P)

Department of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, Nice Cedex, France.

Jean-Philippe Berthet (JP)

Department of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, Nice Cedex, France.

Nicolas Venissac (N)

Department of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, Nice Cedex, France.

Jérome Mouroux (J)

Department of Thoracic Surgery, Centre Hospitalier Universitaire de Nice, Nice Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH